Regulation (EU) 2021/2282 on health technology assessment (HTA) is now in force and will bring important and wide-reaching changes that pharmaceutical companies need to understand.
About the Author
Alexander Natz is secretary general of the European Confederation of Pharmaceutical Entrepreneurs (EUCOPE), a European trade body representing small to medium-sized innovative pharma, biotech and medical technology companies. He is also a lawyer and the founder of the Düsseldorf, Germany-based law firm Novacos Law. Email: alexander.natz@novacos-law.com
Arguably the most important implication of the regulation is the introduction of EU-level joint clinical assessments (JCAs) that will start...








